Efficacy and tolerability of ABT-869 Versus Sorafenib in Advanced hepatocellular carcinoma(HCC)

An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC)

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221053

Enrollment

900

Registered

2010-04-01

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced or metastatic HCC

Interventions

investigational material(s) Generic name etc : ABT-869 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Histologic or cytologic diagnosis with unresectable or metastatic HCC - Child Pugh Class A - ECOG performance status 0-1 - Adequate hematologic, hepatic, and renal function

Exclusion criteria

Exclusion criteria: - Prior systemic (administered intravenously or orally rather than locoregionally) treatment for HCC. - Prior local therapy (including liver-directed therapy) within 4 weeks from entry - Untreated brain or meningeal metastases - Current treatment on another clinical trial - Pregnancy or breastfeeding

Design outcomes

Primary

Measure	Time frame
Overall Survival	—

Secondary

Measure	Time frame
Time to progression (TTP) Objective response rate (ORR)	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026